ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578AM3)(COMPLETED)

This study has been completed.

Sponsors and Collaborators: Schering-Plough
Merck
Information provided by: Schering-Plough
ClinicalTrials.gov Identifier: NCT00552097
  Purpose

The purpose of the study is to determine whether ezetimibe plus simvastatin will be more effective than simvastatin alone in preventing progression of atherosclerosis of the inner layer of the carotid artery.


Condition Intervention Phase
Atherosclerosis
Hypercholesterolemia
Hyperlipoproteinemia Type II
Drug: ezetimibe (plus simvastatin)
Drug: placebo (plus simvastatin)
Phase III

Genetics Home Reference related topics:   hypercholesterolemia  

MedlinePlus related topics:   Cholesterol   Ultrasound  

ChemIDplus related topics:   Simvastatin   Ezetimibe   Vytorin  

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:   Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial)

Further study details as provided by Schering-Plough:

Primary Outcome Measures:
  • Change in ultrasound-determined average carotid artery intima-media thickness (IMT) on a per subject basis between baseline and endpoint. [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • Proportion of subjects with a reduction in ultrasound-determined average carotid artery IMT between baseline and endpoint. [ Time Frame: 24 months ]
  • Change in ultrasound-determined maximum carotid artery IMT on a per subject basis between baseline and endpoint. [ Time Frame: 24 months ]
  • Proportion of subjects developing new carotid artery plaques between baseline and endpoint. [ Time Frame: 24 months ]
  • Change in ultrasound-determined average carotid artery plus average common femoral artery IMT on a per subject basis between baseline and endpoint. [ Time Frame: 24 months ]

Enrollment:   720
Study Start Date:   June 2002
Study Completion Date:   April 2006

Arms Assigned Interventions
EZ/Simva: Experimental Drug: ezetimibe (plus simvastatin)
oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
Placebo/Simva: Placebo Comparator Drug: placebo (plus simvastatin)
tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months

  Eligibility
Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Genotype-confirmed heterozygous familial hypercholesterolemia with written documentation of the genetic diagnosis at the time of screening and LDL-C >=210 mg/dL (5.43 mmol/L), or clinical diagnosis of heterozygous familial hypercholesterolemia, defined as LDL-C >=210 mg/dL (5.43 mmol/L) and at least one of the following:

    • tendinous xanthoma
    • child <18 years of age with hypercholesterolemia (LDL-C >159 mg/dL (4.11 mmol/L)
    • has a sibling with hypercholesterolemia (LDL-C >190 mg/dL [4.91 mmol/L]) and tendinous xanthoma
    • family history with an LDL-C value distribution pattern compatible with dominant autosomal transmission and at least one relative presenting fasting total cholesterol values >348 mg/dL (9.0 mmol/L) after exclusion of secondary causes of dyslipidemia
  • LDL-C >=210 mg/dL (5.43 mmol/L) 1 week before randomization
  • plasma triglyceride level <=400 mg/dL (4.52 mmol/L)

Exclusion Criteria:

  • pregnancy or any other situation, condition, or illness that, in the opinion of the investigator, may interfere with optimal participation in the study
  • presence of an apolipoprotein B gene mutation with confirmed absence of an LDL receptor mutation in either allele
  • undergoing LDL-apheresis or plasma apheresis
  • unsuitable plaque or artery morphology
  • use of certain drugs, foods, or other agents known to alter cholesterol levels or to cause pharmacokinetic interactions with either ezetimibe or simvastatin
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00552097

Sponsors and Collaborators
Schering-Plough
Merck

Investigators
Study Director:     Enrico P. Veltri, MD     Schering-Plough    
  More Information

Publications:

Publications indexed to this study:

Study ID Numbers:   P02578
First Received:   October 31, 2007
Last Updated:   June 19, 2008
ClinicalTrials.gov Identifier:   NCT00552097
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Atherosclerosis
Arterial Occlusive Diseases
Lipid Metabolism, Inborn Errors
Hypercholesterolemia, autosomal dominant
Hyperlipidemias
Simvastatin
Hyperlipoproteinemia Type II
Vascular Diseases
Ezetimibe
Arteriosclerosis
Metabolism, Inborn Errors
Metabolic disorder
Hypercholesterolemia
Hyperlipoproteinemias
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Antimetabolites
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Genetic Diseases, Inborn
Therapeutic Uses
Antilipemic Agents
Enzyme Inhibitors
Cardiovascular Diseases
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 03, 2008




Links to all studies - primarily for crawlers